Company update

May 15, 2024

IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUING

This presentation contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) the ability of its products to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this presentation relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.

These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", "expect", "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "potential", "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's universal registration document, filed with the AMF on July 28, 2022, (the "Universal Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 24 of the Universal Registration Document.

Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.

This presentation is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this presentation does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this presentation may be subject to legal restrictions in certain jurisdictions. Persons who come to know about this presentation are encouraged to inquire about, and required to comply with, these restrictions

All information in the presentation speaks only as of (1) the date hereof, in the case of information about the Company and (2) the date of such information, in the case of information from persons other than the Company. The Company does not undertake any duty to update or revise the information contained herein, publicly or otherwise. The Company has not independently verified any third-party information and makes no representation as to the accuracy or completeness of any such information.

UZEDY® is trademark of Teva Pharmaceuticals

2024, Potential Spectacular Year

UZEDY®	Sales ramp up	✓
mdc-TJK Olanzapine LAI	Positive Phase 3 efficacy results No PDSS (3600 injections)	✓ ✓
mdc-CWM	Encouraging Phase 3 results	✓
Partnering	Strategic collaboration with AbbVie	✓

Growing portfolio and R&D pipeline



mdc-CWM

Intraarticular celecoxib for postoperative inflammation and pain management

► Encouraging Phase 3 results in Total Knee Replacement (TKR)

mdc-CWM, phase 3 study design

Screening

Eligibility Criteria

- Male and/or females indicated for primary, unilateral total knee replacement (TKR)
- Between 45-80 years of age inclusive at the time of signing the informed consent
- Medically stable as determined by the Investigator, based on physical examination, clinical laboratory tests, and 12-lead electrocardiogram (ECG) findings, as well as medical history from patient and pre-study source documents from other care providers

Randomized
1:1

n=150

F14 (sustained release celecoxib) administrated during surgery
+ Multimodal Analgesia
- 0.25 % Bupivacaine HCl (local anesthetic)
- Acetaminophen (analgesic)
- Methocarbamol (muscle relaxant)

Multimodal Analgesia
- 0.25 % Bupivacaine HCl (local anesthetic)
- Acetaminophen (analgesic)
- Methocarbamol (muscle relaxant)

Measured Outcomes



mdc-CWM, phase 3 results

Primary endpoint of time-weighted AUC of pain intensity over 14 days not met

Numerical improvement favoring the treated group observed for

- The primary endpoint
- Secondary endpoints of time-weighted AUC of pain over 3 and 7 days

Other positive outcomes related to inflammation

- Improvement for knee range of motion (ROM) at 6 weeks ($p<0.005$), as well as at 3 months ($p<0.0005$)
- Improvement for swelling at 6 weeks ($p<0.005$) and 3 months ($p<0.05$)
- Improvement of the Timed-Up-and-Go (TUG) test at 6 weeks

Far greater improvement in a sub-group of 108 patients

- Patients had not previously undergone TKR in their contralateral knee
- Improvement in endpoints of time-weighted AUC of pain, opioid consumption, ROM, effusion, and TUG

No new safety signals were identified, and no SAEs were reported as related to F14 treatment

UZEDY®

Monthly and every-two months subcutaneous risperidone for treatment of schizophrenia

► Strong sales ramp up

Extract from Teva's Q1 2024 earnings Call presentation (May 8, 2024)

UZEDY® Launch Building Momentum

UZEDY (risperidone)

Reaffirming 2024 revenues outlook of ~$80M

UZEDY Prescription Growth

UZEDY TRx MOT (months of therapy)

- Differentiated clinical profile we believe to be attractive to patients and HCPs
- Broad access in Fee-for-Service Medicaid
- Strong commercial effort to drive awareness, trial and adoption
- Sales coverage of hospitals, acute treatment centers and community mental health centers

12 | Source: IQVIA NPA (TRx normalized into patient months of therapy equivalent volume based on dosing regimen), large LTC supplier stopped sending IQVIA TRx / NRx / NBRx data starting 7/7/23

Medincell revenue from UZEDY®

Mid- to high-single digit royalties on net sales

Up to $105m of commercial milestones

UZEDY®
► Strong differentiation thanks to BEPO®

Subcutaneous injection (vs. Intramuscular)

No reconstitution needed

Immediate onset of action
(vs. oral supplementation or second injection needed)

Same effect regardless of location of injection

UZEDY®

► Key outcomes from clinical studies

Significant reduction in risk of relapse[1]

- 80% reduction in the risk of relapse with UZEDY® q1m compared vs. placebo

Improvements in PANSS scores[2]

- PANSS scores change favoring UZEDY® (-4.10) over placebo (+1.11) at the end of treatment

Improved quality of life in long-term safety study[3]

- Improved or stable long-term quality of life up to 56 weeks of therapy
- Patients remaining relapse free up to 56 weeks were 98% q1m

1. Data on file. Teva Neuroscience, Inc; UZEDY™ (risperidone) extended-release injectable suspension current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc 2.For exploratory analysis. No determination of statistical significance can be made and no conclusions should be drawn; ITT, intent-to-treat; LS. leastsquares; PAN SS, Positive and Negative Syndrome Scale.. 3. Shine study, Kane JM et al. Presented at the Neuroscience Education Institute Congress; November 9–12, 2023; Colorado Springs, Colorado. Poster 59;

mdc-TJK

Once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine

- **Positive Phase 3 efficacy results**
- **No PDSS to date**

Extract from Teva's Q1 2024 earnings Call presentation (May 8, 2024)

Olanzapine LAI Significant Potential

U.S. Schizophrenia Rx market, current atypical antipsychotic use





LAI	MoT TRx Share
Invega® LAIs (paliperidone)	61%
Aristada® (aripriprazole lauroxil) / Abilify® (aripiprazole)	34%
Risperdal Consta®/ Perseris®/UZEDY® (risperidone)	5%
Zyprexa® Relprevv™ (olanzapine)	<1%

Current Atypical Antipsychotic Use: IQVIA NPA Feb'24 MAT; (LAI TRx normalized into patient months of therapy equivalent volume based on dosing regimen), Oral atypical TRx share: company analysis

Global peak sales source: Evaluate pharma complete data extract for LAI antipsychotics

Trademarks mentioned are the property of their respective owners

UZEDY®, a best-in-class in a well-established market

Janssen (Johnson & Johnson) very successful at building a risperidone LAIs franchise



[1]Metabolite of risperidone

mdc-TJK, a potential first-in-class thanks to a favorable safety profile

Olanzapine LAI from Eli Lilly did not grab potential because of an FDA black box against the risk of **post-injection delirium and sedation syndrome (PDSS)**



The risk of PDSS limits the use of the only other existing olanzapine LAI

PDSS: Sudden and unexpected onset of delirium or sedation after injection

<0.1% of injections and ≈2% of patients

Risk remain for each injection

FDA Blackbox and monitoring requirement

- **Restricted distribution program**
- **Patients must stay at healthcare facility for 3 hours after each injection**

Source: https://www.zyprexarelprevvprogram.com/PDF/CHEPLAPHARM%20Prescribing%20Information.pdf

mdc-TJK is not susceptible to PDSS thanks to subcutaneous injection and advanced controlled release (I)



In-vitro evidence

Release of olanzapine from Zyprexa Relprevv[1] and mdc-TJK in human plasma, 37°C, 100 rpm (30 mg dose), orbital-shaking water bath

Extract from Teva's Q2 earnings call presentation

[1] Zyprexa Relprevv is a trademark of Eli Lilly and Company

mdc-TJK is not susceptible to PDSS thanks to subcutaneous injection and advanced controlled release (II)

Mean (±SD) olanzapine plasma concentrations following single dose TV-44749 sc injections in healthy subjects



Mean (±SD) olanzapine plasma concentrations following single dose TV-44749 sc injections in patients with schizophrenia



Mean (±SD) olanzapine plasma concentrations following three once monthly TV-44749 sc injections in patients with schizophrenia



Phase 1 data

mdc-TJK, SOLARIS, pivotal phase 3 study

Screening

Eligibility Criteria

- Current confirmed diagnosis of schizophrenia according to the DSM-5, for >1 year
- Exacerbation of schizophrenia that started ≤8 weeks prior to screening and would benefit from psychiatric hospitalization or continued hospitalization for symptoms
- Treatment with antipsychotic (other than clozapine) in the past year and must have been responsive based on the investigator's judgment

Period 1
8 weeks

Randomized
1:1:1:1

n=640

- **TV 44749** Low dose
- **TV 44749** medium dose
- **TV 44749** high dose
- Placebo

Period 2
Open label, long term safety
up to 48 weeks

Randomized

- **TV 44749** Low dose
- **TV 44749** medium dose
- **TV 44749** high dose

Primary endpoint: Positive and Negative Syndrome Scale (PANSS) total score (Change from baseline to week 8)

Secondary endpoints include:

- Clinical Global Impression-Severity (CGI-S) scale
- Personal and Social Performance Scale (PSP)
- Safety

Source: ClinicalTrials.gov - Identifier: NCT05693935

mdc-TJK, SOLARIS top line efficacy data

Screening

Eligibility Criteria

- Current confirmed diagnosis of schizophrenia according to the DSM-5, for >1 year
- Exacerbation of schizophrenia that started ≤8 weeks prior to screening and would benefit from psychiatric hospitalization or continued hospitalization for symptoms
- Treatment with antipsychotic (other than clozapine) in the past year and must have been responsive based on the investigator's judgment

Randomized
1:1:1:1

n=640

Period 1
8 weeks

- **TV 44749 Low dose** → **-9.71 points [p<0.001]**
- **TV 44749 medium dose** → **-11.27 points [p<0.001]**
- **TV 44749 high dose** → **-9.71 points [p<0.001]**
- **Placebo**

PANSS score reduction
mean difference in change vs. placebo from baseline to 8 weeks

Primary endpoint: Positive and Negative Syndrome Scale (PANSS) total score (Change from baseline to week 8)

Secondary endpoints include:

- Clinical Global Impression-Severity (CGI-S) scale
- Personal and Social Performance Scale (PSP)

Total score statistically significant
(adjusted for multiplicity)

Source: ClinicalTrials.gov - Identifier: NCT05693935

No PDSS to date

80% of ca. 3600 required injections

mdc-TJK: Accelerating Phase 3 trial

- ✓ **Phase 3 recruitment finalized 9 months ahead of schedule**
- ✓ **Full submission safety database to be available in H2 2024**

Medincell revenue from mdc-TJK

$12m out of $17m of development milestones left

Mid- to high-single digit royalties on net sales

Up to $105m of commercial milestones

Partnering

► Collaboration with AbbVie (April 2024)

Strategic co-development and licensing agreement with AbbVie

Up to 6 Long-Acting Injectable therapies

- Multiple therapeutic areas and indications
- First program candidate selected; formulation activities underway

Medincell to conduct formulation and preclinical activities

AbbVie to conduct clinical development

AbbVie responsible for commercialization globally

Financial metrics

$35 million upfront payment

up to **$1.9 billion**

in potential commercial and development milestones

(up to $315 million for each program)

Tiered

mid-single to low-double digit royalties

What’s next for 2024?

What's next for 2024?

UZEDY®	Sales ramp up	✓
mdc-TJK Olanzapine LAI	Positive Phase 3 efficacy results	✓
	No PDSS (3600 injections)	✓
mdc-CWM	Encouraging Phase 3 results	✓
Partnering	Strategic collaboration with AbbVie	✓

Annual results

June 25, 2024

Q&A